Parexel

PAREXEL International is a contract research organization one of the largest of its kind for the planning and conduct of clinical trials. In Germany the company in Berlin, Freiburg and Mörfelden near Frankfurt is located. The company is based in the United States near Boston, Massachusetts. Parexel has 65 offices in 51 countries and over 9000 employees and is listed on the U.S. Nasdaq exchange (Ticker: PRXL ).

In 2006, Parexel on behalf of the biotechnology company TeGenero in London, a clinical phase I study with the monoclonal antibody TGN1412 by, in which the antibody was first tested on humans. Following administration of TGN1412 occurred within a short time to unexpected severe side effects which required intensive medical care.